Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stryker/Physiotherapy settle DoJ fraud case

This article was originally published in The Gray Sheet

Executive Summary

Stryker and its former outpatient physical therapy business Physiotherapy Associates will pay $16.6 million to settle false claims allegations, the U.S. Department of Justice announces Nov. 14. Physiotherapy will also enter a corporate integrity agreement with the Office of Inspector General. The case stems from two whistleblower suits filed by former employees. Stryker sold Physiotherapy to private equity firm Water Street Healthcare Partners in June. Part of the acquisition agreement limited Stryker's liability for any payments resulting from the DoJ investigation (1"The Gray Sheet" June 11, 2007, p. 10)

You may also be interested in...

Stryker Sells Physical Therapy Business To Private Equity Firm For $150 Mil.

Stryker is getting out of the physical therapy business to focus on its core orthopedic franchise

Coronavirus Demanding Focus Of US FDA’s Antiviral, Other Divisions

Office of New Drugs Director Peter Stein said in an interview that a large amount of coronavirus-related work is arriving at the FDA, but so far staff are keeping up.

Akero Heads To Top Of FGF21 Class In NASH; Genfit Says Pandemic Won’t Delay Phase III

Akero’s FGF21 analog yields 63%-72% relative hepatic fat reduction in Phase IIa study; the company awaits biopsy data hoping to see a fibrotic benefit. Also, Genfit says COVID-19 pandemic should not significantly delay its Phase III NASH readout.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts